Arquivos do dia: Agosto 23, 2021

Estudo randomizado | Posição pronada reduz a necessidade de entubação em pacientes com COVID-19.

23 Ago, 2021 | 13:27h

Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial – The Lancet Respiratory Medicine

Comentário convidado: Awake prone positioning in COVID-19: is tummy time ready for prime time?

Conteúdos relacionados:

RCT: Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19 – no difference in intubation rates compared to standard care.

M-A: Prone positioning of nonintubated patients with Covid-19 improve oxygenation variables without any reported serious adverse events – randomized trials with patient-relevant outcomes such as the need for intubation or mortality rates are required

 

Comentário no Twitter

Awake prone positioning of pts w/ hypoxaemic respiratory failure due to #COVID19 reduces incidence of treatment failure & need for intubation w/o any signal of harm

Meta-trial from the Awake Prone Positioning Meta-Trial Group https://t.co/GuDdjPnVps pic.twitter.com/ZS08uQN1gE

— The Lancet Respiratory Medicine (@LancetRespirMed) August 21, 2021

 

---

Estudo randomizado por cluster | Efeitos de campanha publicitária em larga escala em mídia social sobre viagens em feriados e infecções por COVID-19.

23 Ago, 2021 | 13:25h

Effects of a large-scale social media advertising campaign on holiday travel and COVID-19 infections: a cluster randomized controlled trial – Nature Medicine

 

Comentário no Twitter

Even though we are tired, we should continue trying to educate the public through social media – “Social media messages recorded by health professionals before the winter holidays in the US led to a significant reduction in holiday travel and subsequent COVID-19 infections” https://t.co/kyeKTe4sJn

— gilberto lopes (@GlopesMd) August 22, 2021

 

---

[Preprint] Estudo mostra que as infecções por SARS-CoV-2 em indivíduos já vacinados (“breakthrough infections”) são menos transmissíveis que infecções por SARS-CoV-2 em indivíduos não vacinados.

23 Ago, 2021 | 13:23h

Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study – medRxiv

 

Comentário no Twitter (fio – clique para saber mais)

Did you hear vaccinated people with Delta “have just as much virus in their nose so are just as infectious as unvaccinated”?

Turns out vaccinated people have significantly less culturable virus present at the same Ct count

They are LESS INFECTIOUS 💥 https://t.co/OX0Ul0ntWc pic.twitter.com/3vDQSJ6j84

— Alasdair Munro (@apsmunro) August 22, 2021

 

---

Evidências reforçam que infecções por SARS-CoV-2 em indivíduos já vacinados (“breakthrough infections”) podem facilmente disseminar a variante Delta.

23 Ago, 2021 | 13:21h

Evidence mounts that people with breakthrough infections can spread Delta easily – National Geographic

Estudo original: Shedding of Infectious SARS-CoV-2 Despite Vaccination when the Delta Variant is Prevalent – Wisconsin, July 2021 – medRxiv

 

Comentário no Twitter

The evidence that supports Delta breakthrough infections ability to spread (and why fully vaccinated people need to 😷 up)https://t.co/27NOf6mYCM @NatGeo by @Ecquis w/ studies and input by @GuptaR_lab and @KasenRiemersma

— Eric Topol (@EricTopol) August 20, 2021

 

---

Entre pacientes que recebem vacina de mRNA, sintomas clinicamente significativos são mais frequentes após a 2ª dose, após a 1ª dose em pacientes com infecção prévia por SARS-CoV-2 e naqueles que receberam a vacina da Moderna.

23 Ago, 2021 | 13:19h

Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers – JAMA Internal Medicine

 

Comentário no Twitter

New @JAMA_current paper says @moderna_Tx caused 2.3x the number of "significant" symptoms compared to @pfizer in a sample of 950 people.

Moderna also produced more antibodies. Raising the question of what a third dose, which produces still MORE, will do.https://t.co/drvhhsnpHo

— Alex Berenson (@AlexBerenson) August 16, 2021

 

---

Comentários de estudo | Ventilação não invasiva para pacientes com COVID-19. Estudo Recovery RS.

23 Ago, 2021 | 13:18h

Comentário 1: JC: Non-invasive ventilation for COVID 19 patients. The Recovery RS trial – St Emlyn’s

Comentário 2: An adaptive randomized controlled trial of non-invasive respiratory strategies in acute respiratory failure patients with COVID-19 – The Bottom Line

Estudo original: [Preprint] RCT: non-invasive respiratory strategies in acute respiratory failure in patients with COVID-19 – CPAP reduced the composite outcome of intubation or death within 30 days; high-flow nasal oxygenation was not associated with better outcomes.

---

Estudo laboratorial mostra que a estratégia de vacinação heteróloga AstraZeneca + Pfizer propicia uma imunogenicidade mais potente contra Covid comparada a estratégias homólogas AZ + AZ ou Pfizer + Pfizer.

23 Ago, 2021 | 13:16h

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study – The Lancet Respiratory Medicine

Comentário convidado: Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19

Conteúdos relacionados:

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (vários artigos sobre o tema)

 

Comentário no Twitter

NEW Research—Heterologous ChAdOx1 nCov-19–BNT162b2 immunisation w/ 10–12-week interval is well tolerated & improves immunogenicity vs homologous ChAdOx1 nCov-19 vax w/ 10–12-week interval & BNT162b2 vax w/ 3-week interval

Study from Prof Sander & co https://t.co/VAB54NokSi pic.twitter.com/wfeBsvoKhO

— The Lancet Respiratory Medicine (@LancetRespirMed) August 13, 2021

 

---

[Preprint] Transmissão de SARS-CoV-2 por aerossol em escolas: efetividade teórica de diferentes intervenções – “Intervenções combinadas (i.e., ventilação natural, máscaras e filtração HEPA) foram as mais eficazes (redução ≥ 30 vezes)”.

23 Ago, 2021 | 13:12h

SARS-CoV-2 aerosol transmission in schools: the effectiveness of different interventions – medRxiv

Conteúdo relacionado: The right way to protect our children and return to in-person learning – CNN

 

Comentários no Twitter

Interesting modelling study for schools: (theoretically) most effective is open windows, then masks, then HEPA filter. Would be good to do real world tests though. https://t.co/MDFNqNNUI3 pic.twitter.com/xGSodClipO

— Paul Glasziou (@PaulGlasziou) August 21, 2021

This is not real evidence supporting real policy choices as they are really carried out in the real world.

Instead, this is theoretical bioplausibility spun into a full paper.

I hope folks can still tell the two aparthttps://t.co/znwtiaKZ2g

— Vinay Prasad, MD MPH 🎙️📷 (@VPrasadMDMPH) August 20, 2021

 

---

Vacina CoronaVac em idosos durante a epidemia de Covid-19 associada à variante Gama no Brasil – Efetividade foi de 46,8% contra doença sintomática, de 55,5% contra hospitalização e de 61,2% contra mortes.

23 Ago, 2021 | 13:10h

Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study – The BMJ

Editorial: Real world effectiveness of covid-19 vaccines

Conteúdo relacionado: CoronaVac vaccine: its results are patchy, but the world can’t ignore its usefulness. (vários textos sobre o tema)

---

Dados observacionais do Canadá: Efetividade das vacinas de mRNA contra Covid-19 foi de 91% contra doença sintomática e de 98% contra hospitalização e mortes.

23 Ago, 2021 | 13:08h

Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study – The BMJ

Editorial: Real world effectiveness of covid-19 vaccines

---